B
Bcs Rao
Publications - 8
Citations - 35
Bcs Rao is an academic researcher. The author has contributed to research in topics: Clinical trial & Medicine. The author has an hindex of 2, co-authored 4 publications receiving 18 citations.
Papers
More filters
Journal ArticleDOI
Joints made by RecA protein in the interior of linear duplex DNA: effects of single-stranded ends, length of homology, and dynamic state.
TL;DR: The dynamic state of joints in the interior of duplex DNA strengthens the conclusion that RecA protein dissociates joints when it cannot displace the 5' end of a strand from the recipient duplex.
Posted ContentDOI
Chyawanprash for the prevention of COVID-19 infection among healthcare workers: A Randomized Controlled Trial
Arun Gupta,Amit Madan,Babita Yadav,Richa Singhal,Pallavi S Mundada,Yogesh Kumar Pandey,Riju Agarwal,Rakesh Rana,Arunabh Tripathi,Bhagwan Sharma,Bcs Rao,Bharti Gupta,N. Srikanth,K S Dhiman +13 more
TL;DR: In this article, the effect of the combination of Chyawanprash and standard preventive regimen compared to the use of Standard Preventive Regimen alone on the proportion of RT-PCR confirmed COVID-19 infections among frontline healthcare workers (HCWs).
Posted ContentDOI
Coadministration of AYUSH 64 as an adjunct to Standard of Care in mild and moderate COVID-19: A randomised, controlled, multicentric clinical trial
Arvind Chopra,Girish Tillu,Chaudhary K,Reddy G,Srivastava A,Lakdawala M,Gode D,Reddy H,Tamboli S,Manjit Saluja,S Sarmukkaddam,Manohar S Gundeti,Ashwinikumar A Raut,Bcs Rao,Babita Yadav,N. Srikanth,Bhushan Patwardhan +16 more
TL;DR: In this article, the authors compared the co-administration of an Ayurvedic drug AYUSH 64 as an adjunct to standard of care (SOC) and SOC for efficacy and safety in the management of COVID-19.
Journal ArticleDOI
Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine–A Study Protocol
Arvind Chopra,Preeti Chavan-Gautam,Girish Tillu,Manjit Saluja,Swapnil P. Borse,S. Sarmukaddam,Susmita Chaudhuri,Bcs Rao,B. P. Yadav,N Srikanth,Bhushan Patwardhan +10 more
TL;DR: The safety, immunogenicity and clinical protection offered by a 6-month regimen of Ashwagandha in participants who volunteer to be vaccinated against COVID-19 (COVISHIELDTM) in the ongoing national program of vaccination is studied.
Posted ContentDOI
Randomized, double blind, placebo controlled, clinical trial to study co-administration of Ashwagandha on safety, immunogenicity, and protection with COVID-19 vaccine: A Study Protocol
Arvind Chopra,Preeti Chavan Gautam,Girish Tillu,Manjit Saluja,Swapnil P. Borse,Sanjeev Sarmukaddam,Susmita Chaudhuri,Bcs Rao,Babita Yadav,N. Srikanth,Bhushan Patwardhan +10 more
TL;DR: In this paper, the authors designed a prospective, randomized, double blind, parallel group, placebo controlled, two arm, exploratory study on healthy volunteers receiving the COVID-19 vaccine.